Shares of Aradigm Corp. (ARDM) plunged over 56% on Thursday after two phase III studies evaluating Pulmaquin for the chronic treatment of Non-Cystic Fibrosis Bronchiectasis patients with lung infections with Pseudomonas aeruginosa delivered a mixed bag of results.
from RTT - Biotech http://ift.tt/2fRFDRw
via IFTTT
No comments:
Post a Comment